A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity

  • Neurogenetics. 2019 Aug;20(3):129-143. doi: 10.1007/s10048-019-00578-1.
David B Beck  1 T Subramanian  2 S Vijayalingam  2 Uthayashankar R Ezekiel  3 Sandra Donkervoort  4 Michele L Yang  5 Holly A Dubbs  6 Xilma R Ortiz-Gonzalez  7 Shenela Lakhani  8 Devorah Segal  9 Margaret Au  10 John M Graham Jr  10 Sumit Verma  11 Darrel Waggoner  12 Marwan Shinawi  13 Carsten G Bönnemann  4 Wendy K Chung  14 G Chinnadurai  15
Affiliations
  • 1. National Human Genome Research Institute, National Institutes of Health, 10 Center Drive, Room B3-4129, Bethesda, MD, 20892, USA.
  • 2. Institute for Molecular Virology, Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, E. A. Doisy Research Center, 6th Floor, St. Louis, MO, 63104, USA.
  • 3. Clinical Health Sciences, Saint Louis University, 3437 Caroline Street, Allied Health Building, Suite 3025, Saint Louis, MO, 63104, USA.
  • 4. National Institute of Neurological Disorders and Stroke Neurogenetics Branch, National Institutes of Health, 10 Center Drive Room 2B39, MSC 1477, Bethesda, MD, 20892, USA.
  • 5. University of Colorado Denver, 13123 E. 16th Ave; Box B155, Aurora, CO, 80238, USA.
  • 6. Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
  • 7. Department of Neurology, Pereleman School of Medicine, University of Pennsylvania; Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
  • 8. Center for Neurogenetics, Brain and Mind Research Institute, Weill Cornell Medicine, 413 E 69th Street, New York, NY, 10021, USA.
  • 9. Department of Pediatrics, Division of Child Neurology, Weill Cornell Medicine, 525 E. 68th St, Box 91, New York, NY, 10065, USA.
  • 10. Medical Genetics, Department of Pediatrics, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90068, USA.
  • 11. Division of Pediatric Neurology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • 12. Department of Human Genetics, University of Chicago, Chicago, IL, 60637, USA.
  • 13. Department of Pediatrics, Division of Genetics and Genomic Medicine,, Washington University School of Medicine, St. Louis, MO, 63110, USA.
  • 14. Departments of Pediatrics and Medicine, Columbia University Medical Center, New York, NY, USA. [email protected].
  • 15. Institute for Molecular Virology, Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, E. A. Doisy Research Center, 6th Floor, St. Louis, MO, 63104, USA. [email protected].
Abstract

We previously reported a pathogenic de novo p.R342W mutation in the transcriptional corepressor CTBP1 in four independent patients with neurodevelopmental disabilities [1]. Here, we report the clinical phenotypes of seven additional individuals with the same recurrent de novo CTBP1 mutation. Within this cohort, we identified consistent CtBP1-related phenotypes of intellectual disability, ataxia, hypotonia, and tooth enamel defects present in most patients. The R342W mutation in CtBP1 is located within a region implicated in a high affinity-binding cleft for CtBP-interacting proteins. Unbiased proteomic analysis demonstrated reduced interaction of several chromatin-modifying factors with the CtBP1 W342 mutant. Genome-wide transcriptome analysis in human glioblastoma cell lines expressing -CtBP1 R342 (wt) or W342 mutation revealed changes in the expression profiles of genes controlling multiple cellular processes. Patient-derived dermal fibroblasts were found to be more sensitive to Apoptosis during acute glucose deprivation compared to controls. Glucose deprivation strongly activated the BH3-only pro-apoptotic gene NOXA, suggesting a link between enhanced cell death and NOXA expression in patient fibroblasts. Our results suggest that context-dependent relief of transcriptional repression of the CtBP1 mutant W342 allele may contribute to deregulation of Apoptosis in target tissues of patients leading to neurodevelopmental phenotypes.

Keywords
C-terminal binding protein; Chromatin modifying complex; CtBP1; Neurodevelopmental disease; p.R342W mutation.